Iressa 2nd Line Phase III study in Japan
Study identifier:D791AL00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A multicentre, randomised, open-label, parallel-group, Phase III post-marketing clinical study to compare the overall survival between gefitinib and docetaxel in patients with advanced or metastatic (Stage IIIB/IV), or recurrent non-small cell lung cancer, who have failed one or two chemotherapy regimens
Medical condition
Non-small Cell Lung Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Gefitinib or Docetaxel
Sex
All
Actual Enrollment
484
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Sept 2003
Primary Completion Date: -
Study Completion Date: 01 Nov 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Japan Medical Director
AstraZeneca
